An official website of the United States government
Home
Name
Anktiva
Alternate Names
nogapendekin alfa inbakicept-pmln
Abbreviations
None
Category
Biologic therapy (BRM, immunotherapy)
Subcategory
IL antagonist
NSC Number
None
Primary Site
Bladder
Histology
None
Remarks
April 22, 2024 FDA approved nogapendekin alfa inbakicept-pmln (Anktiva) with Bacillus Calmette-Guérin (BCG) for adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors.
Coding
This drug should be coded
